Covidien to buy BARRX
Covidien, a Mansfield-based medical device maker and supply company, announced it will acquire BARRX Medical for about $325 million. The agreement is expected to be finalized at the end of January. According to Covidien, BARRX, a privately held company, is the leader in treatment of Barrett’s esophagus syndrome, a precancerous condition involving the lining of the esophagus. Covidien has an annual revenue of $11.6 billion and about 41,000 employees worldwide. Its products are sold in more than 140 countries.
- Christine Legere